Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-22T20:31:57.007Z Has data issue: false hasContentIssue false
  • English
  • Français

The diagnosis, clinical findings and treatment options for Parkinson's disease patients attending a tertiary referral voice clinic

Published online by Cambridge University Press:  31 January 2017

N Gibbins ,
R Awad ,
S Harris  and
A Aymat
N Gibbins*
Affiliation:
Department of Otolaryngology, University Hospital Lewisham, London, UK
R Awad
Affiliation:
Department of Speech Therapy, University Hospital Lewisham, London, UK Department of Phoniatric Sciences, Kasr Al-Aini Teaching Hospital, Cairo University, Egypt
S Harris
Affiliation:
Department of Speech Therapy, University Hospital Lewisham, London, UK
A Aymat
Affiliation:
Department of Otolaryngology, University Hospital Lewisham, London, UK
*
Address for correspondence: Mr N Gibbins, Department of Otolaryngology, University Hospital Lewisham, Lewisham High Street, London SE13 6LH, UK E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Parkinson's disease is a degenerative disorder of the central nervous system, mainly affecting motor functions including the voice. The aetiology of dysphonia changes throughout the course of disease progression.

Objectives:

This study aimed to determine the laryngeal changes seen in early-, mid- and late-stage Parkinson's disease. Thirteen patients with Parkinson's disease are presented, representing the largest series of voice patients with Parkinson's disease seen in a voice clinic in the literature.

Method:

Age, gender, severity of handicap caused by voice disorder and possible associated reflux symptoms were examined.

Results:

Laryngeal function appeared to change gradually with progression of the disease, and may have been affected by the presence of pre-existing laryngeal pathology.

Conclusion:

Laryngeal function in Parkinson's disease appears to go through a series of changes that may be helped by both therapeutic and surgical interventions. These patients should be treated within the confines of a voice clinic multidisciplinary model.

Keywords

DysphoniaParkinson DiseaseLarynxLaryngoplastyMedialization LaryngoplastyInjection
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 131 , Issue 4 , April 2017 , pp. 357 - 362
Copyright
Copyright © JLO (1984) Limited 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Presented as a poster at the 15th British Academic Conference of Otolaryngology, 8–10 July 2015, Liverpool, UK.

References

1 Ramig, LO, Fox, C, Sapir, S. Speech treatment for Parkinson's disease. Expert Rev Neurother 2008;8:299–311 Google Scholar
2 Ramig, L, Meyer, T, Fox, C, Blitzer, A, Tagliati, M. Laryngeal function in individuals with Parkinson's disease. Perspectives on Voice and Voice Disorders 2005;15:9–15 Google Scholar
3 Pitcairn, T, Clemie, S, Gray, J, Pentland, B. Non-verbal cues in the self-presentation of parkinsonian patients. Br J Clin Psychol 1990;29:177–84Google Scholar
4 Pitcairn, T, Clemie, S, Gray, J, Pentland, B. Impressions of parkinsonian people from their recorded voices. Br J Clin Psychol 1990;25:85–92 Google Scholar
5 Miller, N, Noble, E, Jones, D, Burn, D. Life with communication changes in Parkinson's disease. Age Ageing 2006;35:235–9Google Scholar
6 Sapir, S, Ramig, LO, Hoyt, P, Countryman, S, O'Brien, C, Hoehn, M. Speech loudness and quality 12 months after intensive voice treatment (LSVT®) for Parkinson's disease: a comparison with an alternative speech treatment. Folia Phoniatr Logop 2002;54:296–303 Google Scholar
7 Berardelli, A, Rothwell, JC, Thompson, PD, Hallett, M. Pathophysiology of bradykinesia in Parkinson's disease. Brain 2001;124:2131–46Google Scholar
8 Ramig, LO, Fox, C, Sapir, S. Parkinson's disease: speech and voice disorders and their treatment with the Lee Silverman Voice Treatment. Semin Speech Lang 2004;25:169–80CrossRefGoogle ScholarPubMed
9 Hammer, MJ, Barlow, SM. Laryngeal somatosensory deficits in Parkinson's disease: implications for speech respiratory and phonatory control. Exp Brain Res 2010;201:401–9Google Scholar
10 Hanson, DG, Gerratt, BR, Ward, PH. Cinegraphic observations of laryngeal function in Parkinson's disease. Laryngoscope 1984;94:348–53Google Scholar
11 Perez, KS, Ramig, LO, Smith, ME, Dromey, C. The Parkinson larynx: tremors and videostroboscopic findings. J Voice 1996;10:354–61Google Scholar
12 Stelzig, Y, Hochhaus, W, Gall, V, Henneberg, A. Laryngeal manifestations in patients with Parkinson disease [in German]. Laryngorhinootologie 1999;78:544–51Google Scholar
13 Yücetürk, AV, Yilmaz, H, Eğrilmez, M, Karaca, S. Voice analysis and videolaryngostroboscopy in patients with Parkinson's disease. Eur Arch Otorhinolaryngol 2002;259:290–3Google Scholar
14 Radad, K, Gille, G, Rausch, W. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep 2005;57:701–12Google Scholar
15 Goberman, A, Coelho, C, Robb, M. Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states. J Commun Disord 2002;35:217–39CrossRefGoogle ScholarPubMed
16 Sanabria, J, Ruiz, PG, Gutierrez, R, Marquez, F, Escobar, P, Gentil, M et al. The effect of levodopa on vocal function in Parkinson's disease. Clin Neuropharmacol 2001;24:99–102 Google Scholar
17 Jiang, J, Lin, E, Wang, J, Hanson, DG. Glottographic measures before and after levodopa treatment in Parkinson's disease. Laryngoscope 1999;109:1287–94Google Scholar
18 Larson, K, Ramig, LO, Scherer, RC. Acoustic and glottographic voice analysis during drug-related fluctuations in Parkinson's disease. J Med Speech Lang Pathol 1994;2:211–26Google Scholar
19 Kompoliti, K, Wang, QE, Goetz, CG, Leurgans, S, Raman, R. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology 2000;54:458–62Google Scholar
20 Trail, M, Fox, C, Ramig, LO, Sapir, S, Howard, J, Lai, EC. Speech treatment for Parkinson's disease. NeuroRehabilitation 2005;20:205–21Google Scholar
21 Biary, N, Pimental, PA, Langenberg, PW. A double-blind trial of clonazepam in the treatment of parkinsonian dysarthria. Neurology 1988;38:255–8Google Scholar
22 Kompoliti, K, Wang, QE, Goetz, CG, Leurgans, S, Raman, R. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology 2000;54:458–62Google Scholar
23 Baker, K, Ramig, LO, Johnson, A, Freed, C. Preliminary speech and voice analysis following foetal dopamine transplants in 5 people with Parkinson's disease. J Speech Hear Res 1997;20:615–26CrossRefGoogle Scholar
24 Ghika, J, Ghika-Schmid, F, Fankhauser, H, Assal, G, Vingerhoets, F, Abanese, A et al. Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects, report of four cases and review of the literature. J Neurosurg 1999;9:313–21CrossRefGoogle Scholar
25 Krack, P, Batir, A, VanBiercom, N, Charbardes, S, Fraix, V, Ardouin, C et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;20:1925–34Google Scholar
26 Törnqvist, AL, Schalén, L, Rehncrona, S. Effects of different electrical parameter settings on the intelligibility of speech in patients with Parkinson's disease treated with subthalamic deep brain stimulation. Mov Disord 2005;20:416–23CrossRefGoogle ScholarPubMed
27 Ramig, LO, Sapir, S, Countryman, S, Pawlas, AA, O'Brien, C, Hoehn, M et al. Intensive voice treatment (LSVT®) for people with Parkinson's disease: a 2 year follow-up. J Neurol Neurosurg Psychiatr 2001;71:493–8CrossRefGoogle ScholarPubMed
28 Ramig, L, Sapir, S, Fox, C, Countryman, S. Changes in vocal intensity following intensive voice treatment (LSVT) in people with Parkinson's disease: a comparison with untreated people and with normal age-matched controls. Mov Disord 2001;16:79–83 Google Scholar
29 Fox, CM, Ramig, LO, Ciucci, MR, Sapir, S, McFarland, DH, Farley, BG. The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders. Semin Speech Lang 2006;27:283–99CrossRefGoogle ScholarPubMed
30 Smith, ME, Ramig, LO, Dromey, C, Perez, KS, Samandari, R. Intensive voice treatment in Parkinson disease: laryngostroboscopic findings. J Voice 1995;9:453–9CrossRefGoogle ScholarPubMed
31 Luschei, ES, Ramig, LO, Baker, KL, Smith, ME. Discharge characteristics of laryngeal single motor units during phonation in young and older adults and in persons with Parkinson disease. J Neurophysiol 1999;81:2131–9Google Scholar
32 Perez, KS, Ramig, LO, Smith, ME, Dromey, C. The Parkinson larynx: tremor and videostroboscopic findings. J Voice 1996;10:354–61Google Scholar
33 Baker, KK, Ramig, LO, Luschei, ES, Smith, ME. Thyroarytenoid activity muscle associated with hypophonia in Parkinson's disease and aging. Neurology 1998;51:1592–8Google Scholar
34 Ramig, LO, Countryman, S, Thompson, LL, Horii, Y. Comparison of two forms of intensive speech treatment for Parkinson disease. J Speech Hear Res 1995;38:1232–51Google Scholar
35 Ramig, LO, Dromey, C. Aerodynamic mechanisms underlying treatment-related changes in vocal intensity in patients with Parkinson's disease. J Speech Hear Res 1996;39:798–807 CrossRefGoogle Scholar